Work

Treatment Profile of First‐Line Immune Checkpoint Inhibitor Combination Therapy for Advanced Renal Cell Carcinoma in Patients With End‐Stage Renal Disease on Dialysis

Year: 2025

Type: article

Abstract: Toshio Takagi has received honoraria from Novartis, BMS, and Ono. Tsunenori Kondo has received honoraria from Pfizer, Novartis, BMS, and Ono. Toshio Takagi is an Editorial Board member of the International Journal of Urology and a co-authors of this article. To minimize bias, they were excluded from all editorial decision-making related to the acceptance of this article for publication.

Source: International Journal of Urology

DOI: 10.1111/iju.70320

Authors: Hiroki Ishihara, Yuki Nemoto, Shinsuke Mizoguchi, Kazuhiko Yoshida, Tsunenori Kondo, Toshio Takagi

Institutions: Tokyo Women's Medical University, Saiseikai Kawaguchi General Hospital, Jyoban Hospital of Tokiwa Foundation, Saiseikai Kazo Hospital, Tokyo Women's Medical University Adachi Medical Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4417497871

FWCI: 0.604

Cites: 7

Cited by: 1

Related to: